Clinical Trial Update: Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated oral varespladib as a broad-spectrum antidote for snakebite envenomation; the trial has been completed and results are posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Snakebite
• Snakebite Envenomation

Drugs mentioned

• Varespladib (varespladib)

Snippet

Sponsor: Ophirex, Inc. | Conditions: Snakebites, Envenoming | Phase 2 | Status: COMPLETED | Results posted: 2025-07-01